Artificial Intelligence in Medical Affairs: A New Paradigm with Novel Opportunities [0.03%]
医学事务中的人工智能:一个充满新机遇的新范式
Emma Fröling,Neda Rajaeean,Klara Sonnie Hinrichsmeyer et al.
Emma Fröling et al.
The advent of artificial intelligence (AI) revolutionizes the ways of working in many areas of business and life science. In Medical Affairs (MA) departments of the pharmaceutical industry AI holds great potential for positively influencing...
Evaluation of the Effectiveness of Additional Risk Minimization Measures for Ixazomib Citrate for Relapsed/Refractory Multiple Myeloma in Japan: A Web-Based Survey Among Pharmacists [0.03%]
日本药师网络调查评价伊沙佐米治疗复发/难治多发性骨髓瘤的附加风险最小化措施的有效性
Yoshiko Maeda,Akihito Abe,Seigo Seki et al.
Yoshiko Maeda et al.
Background: Ixazomib citrate (IXA) in combination with lenalidomide and dexamethasone (IRD therapy) has been approved for the treatment of relapsed or refractory multiple myeloma. In Japan, as these three drugs have diffe...
P.O.L.A.R. Star: A New Framework Developed and Applied by One Mid-Sized Pharmaceutical Company to Drive Digital Transformation in R&D [0.03%]
一种由一家中型制药公司开发和应用的新框架P.O.L.A.R.星:驱动研发的数字化转型
Riccardo Mariani,Maria Carmela De Vuono,Elena Businaro et al.
Riccardo Mariani et al.
Digital transformation has become a cornerstone of innovation in pharmaceutical research and development (R&D). Pharmaceutical companies now have an imperative to embrace transformation, including mid-sized and small-sized companies despite...
Cultivating Excellence: Future-Proofing Medical Affairs with Tailored Talent Programs [0.03%]
卓越人才培养:定制化医疗事务项目助力医药行业发展ABCDEFGHIJKLMNOPQRSTUVWXYZabcdefghijklmnopqrstuvwxyz0123456789%^&*()_+-=~,./'鄄abetic并发症管理——从临床决策到患者教育
Florian Reis,Neda Rajaeean,Reyhan Rose Divarci et al.
Florian Reis et al.
In today's rapidly growing healthcare landscape, the role of Medical Affairs within pharmaceutical companies has transitioned from a traditional support function into a strategic one. Amidst acute challenges such as evolving globalization, ...
Measuring and Understanding Market Exclusivity Length for New Prescription Drugs in France, Australia, and the USA [0.03%]
法国、澳大利亚和美国的新处方药市场排他性期限的度量与分析
Victor L Van de Wiele,Aaron S Kesselheim,Deborah Gleeson et al.
Victor L Van de Wiele et al.
Background: Originator drug manufacturers use several strategies to delay generic competition in the USA, but it remains unclear whether this results in longer market exclusivity compared to other countries. ...
Comparative Study
Pharmaceutical medicine. 2024 Jul;38(4):303-310. DOI:10.1007/s40290-024-00527-w 2024
How Can General Managers Best Leverage Medical Affairs Now and in the Future? [0.03%]
总经理如何才能最好地利用医学事务部门(当前及未来)?
Jon Zdon,Greta-James Chatgilaou,David Henderson et al.
Jon Zdon et al.
General managers (GMs) play a crucial role as enterprise leaders of the country affiliate of multi-national pharmaceutical companies, balancing needs, objectives and governance across all local functions. One such function, Medical Affairs,...
Statistical Signal Detection Algorithm in Safety Data: A Proprietary Method Compared to Industry Standard Methods [0.03%]
安全数据的统计信号检测算法:一种私有方法与行业标准方法的比较研究
Eugenia Bastos,Jeff K Allen,Jeff Philip
Eugenia Bastos
Introduction: Several quantitative methods have been established, in pharmacovigilance, to detect signals of disproportionate reporting (SDRs) from databases containing reports of adverse drug reactions (ADRs). The signal...
Comparative Study
Pharmaceutical medicine. 2024 Jul;38(4):321-329. DOI:10.1007/s40290-024-00530-1 2024
Increasing Diversity, Equity, Inclusion, and Accessibility in Rare Disease Clinical Trials [0.03%]
提高罕见病临床试验中多样性、公平性、包容性和便利性的措施
Gareth Baynam,Simeón Baker,Charles Steward et al.
Gareth Baynam et al.
Diversity, equity, inclusion, and accessibility (DEIA) are foundational principles for clinical trials and medical research. In rare diseases clinical research, where numbers of participants are already challenged by rarity itself, maximizi...
Malia A Belnap,Kaitlin R McManus,Erica N Grodin et al.
Malia A Belnap et al.
Alcohol use disorder (AUD) is a debilitating disorder, yet currently approved pharmacotherapies to treat AUD are under-utilized. The three medications approved by the US Food and Drug Administration (FDA) for the indication of AUD are disul...
Considerations for Planning Effective and Appealing Advisory Boards and Other Small-Group Meetings with Health Care Providers: Importance of Participant Preferences [0.03%]
筹划有效且吸引人的专家咨询会议和其他小型医疗保健提供者会议的考虑因素:参与者的偏好重要性
Cecilia Petrus,Holly Lam
Cecilia Petrus
Background: To optimize cost effectiveness, engagement, reach, inclusivity, insight quality and quantity, and participant satisfaction of pharmaceutical meetings such as advisory boards, the organizers have to carefully w...